{"entity":{"id":"birc5","kind":"target","name":"BIRC5","aka":["baculoviral IAP repeat containing 5","Baculoviral IAP repeat-containing protein 5","EPR-1","survivin","API4"],"tldr":"BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.","summary":"Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localisation of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organisation of the centre spindle by associating with polymerised microtubules.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Trastuzumab, Platinum Compound and Taxane Compound.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:593","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:593"},{"label":"UniProt O15392","url":"https://www.uniprot.org/uniprotkb/O15392/entry"},{"label":"NCBI Gene 332","url":"https://www.ncbi.nlm.nih.gov/gene/332"},{"label":"Ensembl ENSG00000089685","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089685"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["nsclc","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"BIRC5","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:593","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:593","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O15392","url":"https://www.uniprot.org/uniprotkb/O15392/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene BIRC5","url":"https://civicdb.org/features/355","note":"2 evidence items, 0 assertions, 2 variants; diseases: Lung Non-small Cell Carcinoma, HER2 Positive Breast Cancer (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"few-types","specificityNote":"Broadly expressed or essential: HPA lists BIRC5 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA BIRC5: RNA tissue enhanced (bone marrow 36 nTPM, lymphoid tissue 38 nTPM, testis 19 nTPM); blood lineage lineage enriched (T-cells 14 nTPM); high antibody staining in 1 normal tissue; highest cancer staining testis cancer (2 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas BIRC5 tissue","url":"https://www.proteinatlas.org/ENSG00000089685-BIRC5/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000089685 associations","url":"https://platform.opentargets.org/target/ENSG00000089685/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:593","ensembl":"ENSG00000089685","uniprot":"O15392","entrez":"332","firstDescribed":1997,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Ambrosini et al, Nat. Med, 1997, \"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9256286/","biology":"Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localisation of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organisation of the centre spindle by associating with polymerised microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. Location: Cytoplasm; Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus 17q25.3 (HGNC).","whereFound":["Non-small-cell lung cancer: CIViC evidence names this disease","HER2-positive breast cancer: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/birc5/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}